On the annual filings, revenue rose from KRW 193.9 billion in 2022 to KRW 355.8 billion in 2023, an 83.5% increase, then fell to KRW 80.5 billion in 2024, a 77.4% decline, before recovering to KRW 128.6 billion in 2025, up 59.8%. Within 2022 to 2025, 2023 was the largest year and 2024 was the smallest.
Operating profit went from KRW 49.3 billion in 2022 to KRW 142.8 billion in 2023, an increase of 189.7%, and the operating margin moved from 25.4% to 40.1%.
In 2024 the company posted an operating loss of KRW 24.8 billion, an operating margin of -30.8%, and in 2025 operating profit was KRW 2.43 billion, an operating margin of 1.9%.
Net profit attributable to controlling shareholders went from KRW 116.4 billion in 2023 to a net loss of KRW 11.4 billion in 2024 and a profit of KRW 3.11 billion in 2025. Consolidated net income including non-controlling interests was KRW 3.11 billion in 2025, a separate figure from the controlling-shareholder line.
The 2023 surge was supported by COVID-19 test kit deliveries, and the 2024 drop reflected weaker immunoassay demand after the shift to endemic conditions.
Quarterly revenue peaked at KRW 29 billion in the fourth quarter of 2025 and then fell to KRW 22.9 billion, KRW 19.1 billion and KRW 18.9 billion over the next three quarters.
Operating losses widened from KRW 4.86 billion in the third quarter of 2025 to KRW 8.08 billion in the second quarter of 2026 before narrowing to KRW 4.99 billion in the third quarter of 2026. The third-quarter 2026 net loss of KRW 10.9 billion compares with a KRW 3.01 billion profit a year earlier.